Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02192723Completed
Randomised, double-blind trial of haloperidol, Perphenazine, risperidone, olanzapine, quetiapine and 2 more in schizophrenia (6 arms), sponsored by Peking University Huilongguan Hospital. Primary endpoint: Positive and Negative Syndrome Scale at 8 weeks. Started Jun 2012; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02192723.